SearchBox:

Search Term: " Carba "

  Messages 1-4 from 4 matching the search criteria.
Even teethers labeled BPA-free may contain hormone-disruptors Darrell Miller 12/26/16
Detoxify With L-Citrulline Darrell Miller 4/13/09
L-Citrulline 500mg capsules of powder Darrell Miller 9/1/06
REFERENCES Darrell Miller 6/25/05




Even teethers labeled BPA-free may contain hormone-disruptors
TopPreviousNext

Date: December 26, 2016 12:59 PM
Author: Darrell Miller (support@vitanetonline.com)
Subject: Even teethers labeled BPA-free may contain hormone-disruptors





A recent report in the journal Environmental Science and Technology states that 59 different teething devices they tested all came up positive for BPA, which is a known endocrine-disrupting chemical. They also found other dangerous chemicals present in some, but this is one of the most concerning. These chemicals disrupt normal hormone function and can cause abnormal growth and development in children. The real problem is that all of the products were marked as BPA-free. Obviously, stronger measures need to be put in place to make sure companies are properly advertising their products.

Key Takeaways:

  • Some baby teething toys marketed as non-toxic might contain chemicals that could interfere with hormones involved in normal growth and development, a study suggests.
  • All of the products tested positive for one such chemical, bisphenol-A (BPA), even though most of the teethers were marketed as BPA-free, researchers report in the journal Environmental Science and Technology.
  • In animal studies, endocrine-disrupting compounds such as BPA, parabens and antimicrobials have been shown to interfere with hormones and have harmful developmental, reproductive and neurological effects.

"In lab tests for the current study, researchers found BPA as well as a range of different parabens and the antimicrobials triclosan and tricloCarban in most of the teethers."



Reference:

https://www.yahoo.com/news/even-teethers-labeled-bpa-free-may-contain-hormone-193030007.html?ref=gs

(https://vitanetonline.com:443/forums/Index.cfm?CFApp=1&Message_ID=3704)


Detoxify With L-Citrulline
TopPreviousNext

Date: April 13, 2009 03:51 PM
Author: Darrell Miller (dm@vitanetonline.com)
Subject: Detoxify With L-Citrulline

L-citrulline is an alpha-amino acid, first isolated from the watermelon in 1930: hence the name, citrullis being Latin for that fruit, the skin of which is rich in the substance. It is used to enhance performance in sports, particularly through aiding recovery after exercise, and also helps the liver to detoxify the blood.

It is not an essential amino acid in that it is produced by the body and need not be part of your diet. It is a precursor to arginine, which involves the sustained release of nitric oxide in the endothelium that promotes increased flow of blood and the blood vessels as described further below. One of the biochemical pathways for its biosynthesis involves the urea cycle, whereby the toxic ammonia is detoxified into an easily excreted form through its conversion to urea.

The urea cycle consists of five reactions, and citrulline is formed in the second of these. In the first of these, ammonia reacts with bicarbonate to form Carbamoyl phosphate, the phosphate coming from the two molecule of ATP used to energize the reaction. These are converted to adenosine diphosphate (ADP), and the Carbamoyl phosphate then reacts with ornithine to form citrulline, which takes part in step three that eventually leads to the formation of urea.

The second way in which L-citrulline can be biosynthesized is from the oxidation of arginine, a natural amino acid. Arginine is oxidized into N-hydroxyarginine, and then into L-citrulline with the release of nitric oxide.

So that's how it is produced in the body, but how does it help sportsmen, and what part does it play in detoxification? Its effect on recovery after exercise is connected with blood flow. Energy is created in the mitochondria that are contained in every cell off the body. Among the raw materials needed for the production of energy are glucose and oxygen: glucose obtained from the carbohydrates in your diet, and oxygen transported by the hemoglobin or red blood cells.

Both of these rely on blood flow: greater the volume of blood transported to the cells then the greater the ability of these cells to produce energy. During periods of exercise, a good supply of blood is required to provide the raw materials needed for the energy demand of the muscles involved in the exercise. Not only that however, but recovery after exercise involves the replacement of electrolytes, the glycogen used in extensive aerobic and anaerobic exercise and protein replacement, particularly where catabolism has occurred.

In order to supply these raw materials at an adequate rate, it is necessary for the flow of blood to the appropriate muscles to be sufficient. A major restriction to increase blood flow is elasticity of the blood vessels and cells. Although a healthy heart is capable of providing the necessary quantities of blood, and hence of nutrients, any restriction to the flow could cause dangerously high blood pressure.

Nitric oxide plays a signaling role in enlarging blood vessels to allow an increased blood flow when it is needed by the body. It can provide more blood to the stomach during digestion and to the muscles during exercise and recovery.

During hard exercise, nitric oxide can act as a pump that provides blood during exercise and also during recovery. It can therefore provide more rapid gains in lean mass, increased endurance and faster muscle recovery. The way it does this is to send a signal to the smooth muscles to relax; smooth muscles such as those found in veins and arteries, so resulting in vasodilation therefore allowing increased blood flow.

It is the endothelium, the inner lining of blood vessels, which uses the nitric oxide to provide the relaxation signal to the smooth muscles surrounding it. In fact, it is the effect of nitric oxide that enables those living at high altitudes to develop increased stamina and speed over those at lower altitudes, and find more world records seem to be broken during athletics meetings, such as Olympic Games, held at high altitudes. This is because the production of nitric acid is increased at higher altitudes with slightly lower oxygen levels. This is the same effect that is used by vasodilators such as amyl nitrite and Viagra that work by increasing nitric oxide levels in the smooth muscle wall of the blood vessels.

It should not be surprising therefore, that L-citrulline should work in a similar way, since it is intimately involved in the production of nitric oxide. Although this is now generally understood, what part does supplemental citrulline play in the body if it is a non-essential amino acid?

Supplemental L-citrulline is useful in supporting the detoxification of ammonia in the liver when supplies of ornithine Carbamoyl transferase is naturally in short supply. This is the enzyme that catalyzes the reaction between ornithine and Carbamoyl phosphate to form citrulline. Supplements can then help in the removal of ammonia from the blood, and also provide material for the continued production of nitric oxide support muscular activity and its recovery after exercise.

Ammonia itself is a by-product of intensive exercise, and without the urea cycle the body would rapidly become polluted. It is a very toxic product, and causes the death of thousands of people each year. This is generally in people who suffer liver and kidney disease, and the ammonia can be broken down and excreted.

Your brain cells are particularly sensitive to ammonia, and as levels increase the effect progressively ranges from drowsiness thru tremors to coma and eventual death. Any condition, therefore, that reduces the body's capability of metabolizing ammonia is potentially very serious, and any supplement that can help prevent this is valuable.

L-citrulline is believed to help in such situations, although any condition affecting the efficiency of the kidneys or liver and that can cause toxicity due to ammonia or any other toxic substance, should be referred to your physician. It is for its effect in increasing blood flow to provide sufficient raw material, for both the energy needed for high levels of exercise and for muscle recovery, that citrulline is predominantly used as a supplement.

--
Detoxify At Vitanet ®, LLC

(https://vitanetonline.com:443/forums/Index.cfm?CFApp=1&Message_ID=1993)


L-Citrulline 500mg capsules of powder
TopPreviousNext

Date: September 01, 2006 01:03 PM
Author: Darrell Miller (dm@vitanetonline.com)
Subject: L-Citrulline 500mg capsules of powder

L-Citrulline 500mg capsules of powder

 

Now Available!

  • Supports cardiovascular health and sexual function.
  • An amino acid that increases blood flow to the heart and organs.
  • Helps the liver’s detoxification process by converting toxic ammonia into urea for elimination.
  • The body converts l-Arginine to l-Citrulline, a byproduct of which is nitric oxide, a key component in the relaxation and dilation of blood vessels.
  • A readily available nutrient for cardio function, and a preferred source of nitric oxide synthesis.

L-Citrulline is produced in the urea cycle when Carbamoyl phosphate is converted to Citrulline in the ornithine Carbamoyl transferase reaction. When endogenous supplies of ornithine Carbamoyl transferase are insufficient, supplemental L-Citrulline has been shown to support ammonia incorporation and liver detoxification of ammonia.



--
Buy Citrulline at Vitanet

(https://vitanetonline.com:443/forums/Index.cfm?CFApp=1&Message_ID=1367)


REFERENCES
TopPreviousNext

Date: June 25, 2005 08:13 PM
Author: Darrell Miller (dm@vitanetonline.com)
Subject: REFERENCES

REFERENCES

1 a. The Surgeon General’s “Nutrition and Health Report.” b. The Centers for Disease Control and Prevention’s “National Health and Examination Survey (NHANES III)” c. The National Academy of Science’s. Diet and Health Report: Health Promotion and Disease Objectives (DHHS Publication No. (PHS) 91-50213, Washington, DC: US Government Printing Office, 1990). e. Dietary Guidelines for Americans. 2 Rolls BJ. Carbohydrates, fats, and satiety. Am J Clin Nutr 1995; 61(4 Suppl):960S-967S. 3 McDowell MA, Briefel RR, Alaimo K, et al. Energy and macronutrient intakes of persons ages 2 months and over in the United States: Third National Health and Nutrition Examination Survey, Phase 1:1988-91. Advance data from vital and health statistics of the Centers for Disease Control and Prevention; No. 255. Hyattsville, Maryland: National Center for Health Statistics; 1994. 4 Center for Science in the Public Interest and McDonald’s Nutrition and You—A guide to Healthy Eating at McDonald’s: McDonald’s Corp,1991. 5 Bray GA. Appetite Control in Adults. In: Fernstrom JD, Miller GD eds. Appetite and Body Weight Regulation. Boca Raton: CRC Press, 1994:1-92. 6 Michnovicz JJ. How to Reduce Your Risk of Breast Cancer. New York: Warner Book Inc. 1994:54. 7 Carcinogens and Anticarcinogens in the Human Diet. National Research Council Report, National Academy of Sciences, 15 Feb. 1996. 8 Van Tallie TB. Obesity: adverse effects on health and longevity. Am J Clin Nutr 1979:32: 2723-33. 9 Somer E, M.A. R.D. Nutrition for Women. New York: Henry Hold and Company, 1993:273. 10 Swaneck GE, Fishman J. Covalent binding of the endogenous estrogen 16A-hydroxyestrone to estradiol in human breast concer cells: characterization and intranuclear localization. Proc Natl Acad Sci USA 1988:85;7831-5. 11 Colditz GA. Epidemiology of breast cancer. Findings from the nurses’ health study. Cancer1993;714:1480-9. 12 Hennen WJ. Breast Cancer Risk Reduction. The effects of supplementation with dietary indoles. Unpublished report 1992. 13 Deslypere BJ. Obesity and cancer. Metabolism 1995;44(93):24-7. 14 Somer E, M.A. R.D. Nutrition for Women. New York: Henry Hold and Company, 1993:281. 15 Whittemore AS, Kolonel LN, John M. Prostate cancer in relation to diet, physical activity, and body size in blacks, whites, and Asians in the United States and Canada. J Natl Cancer Inst 1995;87(9):629-31. 16 Key T. Risk factors for prostate cancer. Cancer Survivor 1995;23:63- 77. 17 Kondo Y, Homma Y, Aso Y, Kakizoe T. Promotional effects of twogeneration exposure to a high-fat diet on prostate carcinogenisis in ACI/Seg mice. Cancer Res 1994;54(23):6129-32. 18 Wang Y, Corr JG, Taler HT, Tao Y, Fair WR, Heston WD. Decreased growth of established human prostate LNCaP tumors in nude mice fed a low-fat diet. J Natl Cancer Inst. 1995;87(19):1456-62. 19 Nixon DW. Cancer prevention clinical trials. In-Vivo 1994;8(5):713-6. 20 Key T. Micronutrients and cancer aetiology: the epidmiological evidence. Proceed Nutr Soc 1994;53(3):605-14. 21 Gorbach SL, Goldin BR. The intestinal microflora and the colon cancer connection. Reviews of Infectious Diseases 1990;12(Suppl 2):S252-61. 22 Shrapnel WS, Calvert GD, Nestel PJ, Truswell AS. Diet and coronary heart disease. The National Heart Foundation of Australia. Med J Australia. 1995;156(Suppl):S9-S16. 23 Ellis JL, Campos-Outcalt D. Cardiovascular disease risk factors in native Americans: a literature review. Am. J. Preventive Med 1994;10(5):295-307. 24 DiBianco R. The changing syndrome of heart failure: an annotated review as we approach the 21st century. J. Hypertension 1994; 12(4 Suppl):S73- S87. 25 Van Itallie TB. Obesity: adverse effects on health and longevity. Am J Clin Nutr 1979;32(suppl):2723-33. 26 Kestin M, Moss R, Clifton PM, Nestel PJ. Comparative effects of three cereal brans on plasma lipids, blood pressure and glucose metabolism in mildly hyper-cholesterolemic men. Am J Clin Nutr 1990;52(4):661-6. 27 Story JA. Dietary fiber and lipid metabolism. In: Spiller GA, Kay RM. eds. Medical Aspects of Dietary Fiber. Penun Medical; New York, 1980, p.138. 28 Stein PP, Black HR. The role of diet in the genesis and treatment of hypertension. Med. Clin. North America. 1993;77(4):831-47. 29 Olin JW. Antihypertensive treatment in patients with peripheral vascular disease. Cleve. Clin. J. Medicine. 1994;61(5):337-44. 30 Tinker LF. Diabetes Mellitus—a priority health care issue for women. J. Am. Dietetic Association. 1994;94(9):976-85. 31 Gaspard UJ, Gottal JM, van den Brule FA. Postmenopausal changes of lipid and glucose metabolism: a review of their main aspects. Maturitas. 1995;21(3):71-8. 32 Coordt MC, Ruhe RC, McDonald RB. Aging and insulin secretion. Proc. Soc. Exp. Biology and Medicine. 1995;209(3):213-22. 33 Felber JP. From Obesity to Diabetes. Pathophysiological Considerations. Int. Journal of Obesity 1992;16:937-952. 34 Gillum RF. The association of body fat distribution with hypertension, hypertensive heart disease, coronary heart disease, diabetes, and cardiovascular risk factors in men and women age 18-79. J Chronic Diseases 1987;40:421-8. 35 Haffner SM, Stern MP, Hazuda HP, et al. Role of obesity and fat distribution in non-insulin-dependent diabetes mellits in Mexican Americans and non- Hispanic whites. Diabetes Care 1986;9:153-61. 36 Bonadonna RC, deFronzo RA. Glucose metabolism in obesity and type 2 diabetes. Diabetes and Metabolism. 1991;17(1 Pt. 2):12-35. 37 Shoemaker JK, Bonen A. Vascular actions of insulin in health and disease. Canadian J. of Applied Physiology. 1995;20(2):127-54. 38 Resnick LM. Ionic Basis of Hypertension, Insulin Resistaince, Vascular Disease, and Related Disorders. The Mechanism of ‘Syndrome X’. Am. J. Hypertension. 1993;6(suppl):123S-134S. 39 Trautwein EA. Dietetic influences on the formation and prevention of cholesterol gallstones. Z. Ernahrugswiss. 1994;33(1):2-15. 40 Cicuttini FM, Spector TD. Osteoarthritis in the aged. Epidemiological issues and optimal management. Drugs and Aging. 1995;6(5):409-20. 41 Melnyk MG, Wienstein E. Preventing obesity in black women by targeting adolescents: a literature review. J Am. Diet. Association. 1994;94(4):536-40. 42 Robinson BE, Gjerdingen Dk, Houge DR. Obesity: a move from traditional to more patient-oriented management. J. Am. Board of Family Practice. 1995;8(2):99-108. 43 Dulloo AG, Miller DS. Reversal of Obesity in the Genetically Obese fa/fa Zucker Rat with an Ehpedrine/Methylxanthines Thermogenic Mixture. J. Nutrition. 1987;117:383-9. 44 Dulloo AG, Miller DS. The thermogenic properties of ephedrin/methylxanthine mixtures: animal studies. Am J Clinical Nutr. 1986;43:388-394. 45 Richelsen B. Health risks of obesity. Significance of the regional distri-bution of adipose tissue. Ugeskr. Laeger. 1991;153(13):908-13. 46 Lissner L, Heitmann BL. Dietary fat and obesity: Evidence from epidemiology. European J. Clinical Nutrition. 1995;49(2):79-90. 47 Lissner L, Heitmann BL. The dietary fat: Carbohydrate ratio in relation to body weight, Current Opinion in Lipidology. 1995;6(1):8-13. 48 Ravussin E. Energy metabolism in obesity. Studies in the Pima Indians. Diabetes Care. 1993;16(1):232-8. 49 O’Dea K. Westernisation, insulin resistance and diabetes in Australian aborigines. Med J. Australia. 1991;155(4):258-64. 50 Bailey C. Fit or Fat . Houghton Mifflen, Boston, 1991. 51 McCarty MF. Optimizing Exercise for Fat Loss. Unpublished report. 52 Weinsier RL, Schutz Y, Bracco D. Reexamination of the relationship of resting metabolic rate and fat-free mass and the the metabolically active components of fat-free mass in humans. Am. J. Clinical Nutrition. 1992;55(4):790-4. 53 Evans WJ. Exercise, nutrition and aging. J. Nutrition. 1992;122(3 suppl):796-801. 54 Schlicker SA, Borra ST, Regan C. The weight and fitness status of United States children. Nutrition Reviews. 1994;52(1):11-7. 55 Raben A, Jensen ND, Marckmann P, Sandstrom B and Astrup A. Spontaeous weight loss during 11 weeks’ ad libitum intake of a low fat/high fiber diet in young, normal weight subjects. Stockholm Press. 1995;916-23. 56 Blundell JE, Cotton JR, Delargy H, Green S, Greenough A, King NA, Lawton, CL. The fat paradox: fat-induced satiety signals versus high fat overconsumption. Short Communication 1995:832-835. 57 Reinhold RB. Late results of gastric bypass surgery for morbid obesity. J Am Coll Nutr 1994;13(4):307-8. 58 McCredie M, Coates M Grulich A. Cancer incidence in migrants to New South Wales (Australia) from the Middle East, 1972-1991. Cancer Causes Control 1994:5(5):414-21. 59 Schiff ER, Dietschy JM. Steatorrhea Associated with Disordered Bile Acid Metabolism. Am. J. Digestive Diseases. 1969;14(6) 60 Nauss JL , Thompson JL and Nagyvary J. The binding of micellar lipids to Chitosan. Lipids. 1983;18(10):714-19. 61 Braconnot H, Sue la natrue ces champignons. Ann Chim Phys 1811;79:265. 62 Odier A. Memoire sur la composition chemique des parties cornees des insectes. Mem Soc Hist Nat Paris 1823;1:29. 63 Johnson EL, Peniston QP. Utilization of shellfish waste for chitin and Chitosan production. Chp 19 In: Chemistry and Biochemistry of Marine Food Products. Martin RE, Flick GJ, Hebard CE and Ward DR (eds.) 1982. p.415-. AVI Publishing Co., Westport, CT. 64 Shahram H. Seafood waste: the potential for industrial use. Kem Kemi 1992;19(3),256-8. 65 Rouget C. Des substances amylacees dans le tissue des animux, specialement les Articules (Chitine). Compt Rend 1859;48:792. Commission on Natural Health Products. 1995 67 Peniston QP and Johnson EL. Method for Treating an Aqueous Medium with Chitosan and Derivatives of Chitin to Remove an Impurity. US Patent 3,533,940. Oct. 30:1970. 68 Poly-D-Glucosamine (Chitosan); Exemption from the Requirement of a Tolerance. Federal Register. 1995;60(75):19523-4. Rules and Regulations. Environmental Protection Agency 40 CFR Part 180. April, 19, 1995. 69 Arul J. “Use of Chitosan films to retard post-harvest spoilage of fruits and vegetables,” Chitin Workshop. ICNHP, North Carolina State University, Raleigh, NC. 70 Karlsen J, Skaugrud O. “Excipient properties of Chitosan,” Manufacturing Chemist. 1991;62:18-9. 71 Winterowd JG, Sandford PA. Chitin and Chitosan. In: Food Polysaccharides and their Applications. Ed: Stephen AM. Marcel Dekker 1995. 72 Chitin Workshop. ICNHP, North Carolina State University, Raleigh, NC. 73 Advances in Chitin and Chitosan. Eds: CJ Brine, PA Sandford, JP Zikakis. Elsevier Applied Science. London. 1992. 74 Chitin in Nature and Technology. Eds: R Muzzarelli, C Jeuniaux, GW Gooday. Plenum Press, New York. 1986. 75 Zikakis, JP. Chitin, Chitosan and Related Enzymes. Academic Press, Inc. 1984. 76 Abelin J and Lassus A. Fat binder as a weight reducer in patients with moderate obesity. ARS Medicina, Helsinki, Aug- October, 1994. 77 Kanauchi O, Deuchi K, Imasato Y, Shizukuishi M, Kobayashi E. Increasing effect of a Chitosan and ascorbic acid mixture on fecal dietary fat excretion. Biosci Biotech Biochem 1994;58(9):1617-20. 78 Maezaki Y, Tsuji K, Nakagawa Y, et al. Hypocholesterolemic effect of Chitosan in adult males. Biosci Biotchnol Biochem1993;57(9):1439-44. 79 Kobayashi T, Otsuka S, Yugari Y. Effect of Chitosan on serum and liver cholesterol levels in cholesterol-fed rats. Nutritional Rep. Int., 1979;19(3):327-34. 80 Sugano M, Fujikawa T, Hiratsuji Y, Hasegawa Y. Hypocholesterolemic effects of Chitosan in cholesterol-fed rats. Nutr Rep. Int. 1978;18(5):531-7. 81 Vahouny G, Satchanandam S, Cassidy M, Lightfoot F, Furda I. Comparative effects of Chitosan and cholestryramine on lymphatic absorption of lipids in the rat. Am J Clin Nutr, 1983;38(2):278-84 82 Suzuki S, Suzuki M, Katayama H. Chitin and Chitosan oligomers as hypolipemics and formulations containing them. Jpn. Kokai Tokkyo Koho JP 63 41,422 [88,422] 22 Feb1988. 83 Ikeda I, Tomari Y, Sugano M. Interrelated effects of dietary fiber on lymphatic cholesterol and triglyceride absorption in rats. J Nutr 1989;119(10):1383- 7. 84 LeHoux JG and Grondin F. Some effects of Chitosan on liver function in the rat. Endocrinology. 1993;132(3):1078-84. 85 Fradet G, Brister S, Mulder D, Lough J, Averbach BL. “Evaluation of Chitosan as a New Hemostatic Agent: In Vitro and In Vivo Experiments In Chitin in Nature and Technology. Eds: R Muzzarelli, C Jeuniaux, GW Gooday. Plenum Press, New York. 1986. 86 Malette W, Quigley H, Gaines R, Johnson N, Rainer WG. Chitosan A New Hemostatic. Annals of Thorasic Surgery. 1983;36:55. 87 Malette W, Quigley H, Adickes ED. Chitosan effect in Vascular Surgery, Tissue Culture and Tissue Regeneration. In R Muzzarelli, C Jeuniaux, GW Gooday, Eds: Chitin in Nature and Technology. Plenum Press, New York. 1986. 88 Okamoto Y, Tomita T, Minami S, et al. Effects of Chitosan on experimental abscess with Staphylococcus aureus in dogs. J. Vet. Med., 1995;57(4):765-7. 89 Klokkevold PR, Lew DS, Ellis DG, Bertolami CN. Effect of Chitosan on lingual hemostasis in rabbits. Journal of Oral-Maxillofac-Surg, 1991;Aug. 49(8):858-63. 89 Surgery, Tissue Culture and Tissue Regeneration. In Chitin in Nature and Technology. Eds: R Muzzarelli, C Jeuniaux, GW Gooday. Plenum Press, New York. 1986. 90 Hiroshi S, Makoto K, Shoji A, Yoshikazu S. Antibacterial fiber blended with Chitosan. Sixth International Conference on Chitin and Chitosan. Sea Fisheries Institute, Gdynia, Poland. August 1994;16-19. 91 Shimai Y, Tsukuda K, Seino H. Antiacne preparations containing chitin, Chitosan or their partial degradation products. Jpn. Kikai Tokkyo Koho JP 04,288,017 [92,288,017] 13 Oct 1992. 92 Suzuki K, Okawa Y, Suzuki S, Suzuki M. Candidacidal effect of peritoneal exudate cells in mice administered with chitin or Chitosan: the role of serine protease in the mechanism of oxygen-independent candidacidal effect. Microbiol Immunol. 1987;31(4):375-9. 93 Sawada G, Akaha Y, Naito H, Fujita M. Synergistic food preservatives containing organic acids, Chitosan and citrus seed extracts. Jpn, Kokai Kokkyo Koho JP 04 27,373 [92 27,373] 30 Jan 1992. 94 Min H-K, Hatai K, Bai S. Some inhibitory effects of Chitosan on fishpathogenic oomycete, Saprolegnia parasitic. Gyobyo Kenkyu, 1994;29(2):73-4. 95 Nelson JL, Alexander JW, Gianotti L, Chalk CL, Pyles T. The influence of dietary fiber on microbial growth in vitro and bacterial translocation after burn injury in mice. Nutr 1994;10(1):32-6. 96 Ochiai Y, Kanazawa Y. Chitosan as virucide. Jpn Kokai Tokkyo Koho 79 41,326. 97 Hillyard IW, Doczi J, Kiernan. Antacid and antiulcer properties of the polysaccharide Chitosan in the rat. Proc Soc Expl Biol Med 1964; 115:1108-1112. 98 Shibasaki K, Sano H, MatsukuboT, Takaesu Y. pH response of human dental plaque to chewing gum supplemented with low molecular Chitosan. Bull- Tokyo-Dent-Coll, 1994:35(2): 61-6. 99 Kato H, Okuda H. Chitosan as antihypertensive. Jpn. Kikoi Tokyo Koho JP 06 56,674 [94 56,674] 100 Kato H, Taguchi T. Mechanism of the rise in blood pressure by sodium chloride and decrease effect of Chitosan on blood pressure. Baiosaiensu to Indasutori 1993;51(12):987-8. 101 Muzzarelli R, Biagini G, Pugnaoni A, Filippini O, Baldassarre V, Castaldini C, and Rizzoli C. Reconstruction of Periodontal Tissue with Chitosan. Biomaterials. 1989;10:598-603. 102 Sapelli P, Baldassarre V, Muzzarelli R, Emanuelli M. Chitosan in Dentistry. In Chitin in Nature and Technology. Eds: R Muzzarelli, C Jeuniaux, GW Gooday. Plenum Press, New York. 1986. 103 Borah G, Scott G, Wortham K. Bone induction by Chitosan in endochrondral bones of the extremities. In Advances in Chitin and Chitosan. Eds: CJ Brine, PA Sandford, JP Zikakis. Elsevier Applied Science. London. 1992. 104 Ito F. Role of Chitosan as a supplementary food for osteoporosis. Gekkan Fudo Kemikaru, 1995;11(2):39-44. 105 Nakamura S, Yoshioka T, hamada S, Kimura I. Chitosan for enhancement of bioavailability of calcium. Jpn. Kokai Tokkyo Koho JP 07 194,316 [95 194,316] 01 Aug 1995. 106 Maekawa A, Wada M. Food Containing chitin or its derivatives for reduction of blood and urine uric acid. Jpn. Kokai Tokkyo Koho JP 03 280,852 [91 280,852], 11 Dec 1991. 107 Weisberg M, Gubner R. Compositions for oral administration comprising Chitosan and a pharmaceutically acceptable carrier. Antacid preparations for alleviating gastric hyperacidity. U.S. patent 3257275 108 Kanauchi O, Deuchi K, Imasato Y, Shizukuishi M, Kobayashi E. Mechanism for the inhibition of fat digestion by Chitosan and for the synergistic effect of ascorbate. Biosci Biotech Biochem1995;59(5):786-90. 109 McCausland CW. Fat Binding Properties of Chitosan as Compared to Other Dietary Fibers. Private communication. 24 Jan1995. 110 Deuchi K, Kanauchi O, Imasato Y, Kobayashi E. Biosci Biotech Biochem. 1994:58,1613-6. 111 Ebihara K, Schneeman BO. Interaction of bile acids, phospholipids, cholesterol and triglyceride with dietary fibers in the small intestine of rats. J Nutr 1989;119(8):1100-6. 112 Weil A, M.D. Natural Health Natural Medicine: Boston: Houghton Mifflin, 1990:182. 113 Chen Y-H, Riby Y, Srivastava P, Bartholomew J, Denison M, Bjeldanes L. Regualtion of CYP1A1 by indolo[3,2-b]Carbazole in murine hepatoma cells. J Biol Chem 1995;270(38):22548-55. 114 Intestinal Absorption of metal ions and chelates. Ashmead HD, Graff DJ, Ashmead HH. Charles C Thomas, Springfield, IL 1985. 115 Nutrient Interactions. Bodwell CE, Erdman JW Jr. Marcel Dekker New York 1988. 116 Heleniak EP, Aston B. Prostaglandins, Brown Fat and Weight Loss. Medical Hypotheses 1989;28:13-33. 117 Connor WE, DeFrancesco CA, Connor SL. N-3 fatty acids from fish oil. Effects on plasma lipoproteins and hypertriglyceridemic patients. Ann NY Acad Sci 1993;683:16-34. 118 Conte AA. A non-prescription alternative in weight reduction therapy. The Bariatrician Summer 1993:17-19. 119 McCarty MF. Inhibition of citrate lyase may aid aerobic endurance. Unpublished manuscript. 120 Bray GA. Weight homeostasis. Annual Rev Med 1991;42:205-216. 121 Dulloo AG, Miller DS. The thermogenic properties of Ephedrin/Methylxanthine mixtures: Human studies. Intl J Obesity 986;10:467-481. 122 Arai K, Kinumaki T, Fujita, T. Bulletin Tokai Regional Fisheries Res Lab. 1968;No. 56. 123 Bough WA. Private communication. 124 Freidrich EJ, Gehan, EA, Rall DP, Schmidt LH, Skipper HE. Cancer Chemotherapy Reports 1966;50(4):219-244. 125 A Drovanti, AA Bignamini, AL Rovati. Therapeutic activity of oral glucosamine sulfate in osteoarthritis: A placebo-controlled double-blind investigation. Clinical Therapeutics 1980;3(4):260-272. 126 K Deuchi, O Kanauchi, M Shizukuishi, E Kobayashi. Continuous and massive intake of Chitosan affects mineral and fat-soluble vitamin status in rats fed on a high-fat diet. Biosci. Biotech. Biochemistry. 1995;59(7):1211-6. 127 . BesChitin W in Chitin Wound Healing (video), Unitika Corporation, April 1992.

(https://vitanetonline.com:443/forums/Index.cfm?CFApp=1&Message_ID=507)



VitaNet ® LLC. Discount Vitamin Store.